Maiga Mariama C, Ahidjo Bintou Ahmadou, Maiga Mamoudou, Bishai William R
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali.
Antimicrob Agents Chemother. 2015 Dec;59(12):7888-90. doi: 10.1128/AAC.02145-15. Epub 2015 Oct 5.
With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).
随着磷酸二酯酶抑制剂（PDE-Is）在缩短结核病治疗时间方面显示出显著前景，我们评估了已获美国食品药品监督管理局（FDA）批准的4型PDE-I药物罗氟司特在急性和慢性小鼠结核病模型中的作用。单独使用时，罗氟司特对肺部细菌负荷和死亡率没有影响。然而，当罗氟司特与异烟肼联合使用时，观察到肺部细菌负荷有所降低。这些数据表明，罗氟司特可能是结核病宿主导向治疗（HDT）的一个良好候选药物。
